Aptamer against midkine and use thereof

Details Aptamer against midkine and use thereof Aptamer against midkine and use thereof

2007-11-14

2011-12-20

Gibbs, Terra C. (Department: 1635)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S023100, C536S024300, C536S024330, C514S04400A

Reexamination Certificate

active

08080649

ABSTRACT:
Provided is a high-quality aptamer against midkine.An aptamer possessing an inhibitory activity against midkine; a complex comprising an aptamer possessing a binding activity or inhibitory activity against midkine and a functional substance (for example, affinity substances, substances for labeling, enzymes, drug delivery vehicles, drugs and the like); a pharmaceutical drug, cell migration inhibitor, diagnostic reagent, labeling agent and the like comprising an aptamer possessing a binding activity or inhibitory activity against midkine, or a complex comprising the aptamer and a functional substance; a cell migration inhibitor, a diagnostic reagent, a labeling agent and the like.

REFERENCES:
patent: 6-172218 (1994-06-01), None
patent: 2000-354487 (2000-12-01), None
patent: 2004-344008 (2004-12-01), None
patent: 2006-141305 (2006-06-01), None
patent: 2006-211905 (2006-08-01), None
patent: 99/03493 (1999-01-01), None
patent: 00/10608 (2000-03-01), None
patent: 2004/078210 (2004-09-01), None
patent: 2004/085642 (2004-10-01), None
patent: 2006/016571 (2006-02-01), None
Karl Thiel. Nature Biotechnology, 2004 vol. 22, No. 6, pp. 649-651.
K. Inoh et al., “Doxorubicin-Conjugated Anti-Midkine Monoclonal Antibody as a Potential Anti-Tumor Drug”, Japanese Journal of Clinical Oncology, vol. 36, No. 4, pp. 207-211, 2006.
W. Iwasaki et al., “Solution structure of midkine, a new heparin-binding growth factor”, The EMBO Journal, vol. 16, No. 23, pp. 6936-6946, 1997.
K. Kadomatsu et al., “cDNA Cloning and Sequencing of a New Gene Intensely Expressed in Early Differentiation Stages of Embryonal Carcinoma Cells and in Mid-Gestation Period of Mouse Embryogenesis”, Biochemical and Biophysical Research Communications, vol. 151, No. 3, pp. 1312-1318, Mar. 30, 1988.
M. Tomomura et al., “A Retinoic Acid-Responsive Gene, MK, Found in the Teratocarcinoma System”, The Journal of Biological Chemistry, vol. 265, No. 18, pp. 10765-10770, Jun. 25, 1990.
T. Muramatsu, “Midkine and Pleiotrophin: Two Related Proteins Involved in Development, Survival, Inflammation and Tumorigenesis”, J. Biochem., vol. 132, pp. 359-371, 2002.
A. D. Ellington et al., “In vitro selection of RNA molecules that bind specific ligands”, Nature, vol. 346, pp. 818-822, Aug. 30, 1990.
C. Tuerk et al., “Systematic Evolution of Ligands by Exponential Enrichment: RNA Ligands to Bacteriophage T4 DNA Polymerase”, Science, vol. 249, pp. 505-510, Aug. 3, 1990.
M. Horiba et al., “Neointima formation in a restenosis model is suppressed in midkine-deficient mice”, The Journal of Clinical Investigation, vol. 105, No. 4, pp. 489-495, Feb. 2000.
H. B. Zeyneloglu et al., “The effect of monocyte chemotactic protein 1 in intraperitoneal adhesion formation in a mouse model”, Am. J. Obstet. Gynecol., vol. 179, pp. 438-443, 1998.
A. Murasugi et al., “Efficient Production of Recombinant Human Pleiotrophin in Yeast,Pichia pastoris”, Biosci. Biotechnol. Biochem., vol. 67, No. 10, pp. 2288-2290, 2003.
H. Muramatsu et al., “Purification of Recombinant Midkine and Examination of its Biological Activities: Functional Comparison of New Heparin Binding Factors”, Biochemical and Biophysical Research Communications, vol. 177, No. 2, pp. 652-658, Jun. 14, 1991.
H. Muramatsu et al., “Localization of Heparin-Binding, Neurite Outgrowth and Antigenic Regions in Midkine Molecule”; Biochemical and Biophysical Research Communications, vol. 203, No. 2, pp. 1131-1139, Sep. 15, 1994.
K. Inoh et al., “Midkine, a heparin-binding cytokine, plays key roles in intraperitoneal adhesions”, Biochemical and Biophysical Research Communications, vol. 317, pp. 108-113, 2004.
J. Hobbs et al., “Polynucleotides Containing 2′-Amino-2′-deoxyribose and 2′-Azido-2′-deoxyribose”, Biochemistry, vol. 12, No. 25, pp. 5138-5145, 1973.
Y. Takei et al., “Antisense Oligodeoxynucleotide Targeted Midkine, a Heparin-binding Growth Factor, Suppresses Tumorigenicity of Mouse Rectal Carcinoma Cells”, Cancer Research, vol. 61, pp. 8486-8491, Dec. 1, 2001.
H. Muramatsu et al., “Midkine, A Retinoic Acid-Inducible Growth/Differentiation Factor: Immunochemical Evidence for the Function and Distribution”, Developmental Biological, vol. 159, pp. 392-402, 1998.
T. Takada et al., “Midkine, A Retinoic Acid-Inducible Heparin-Binding Cytokine in Inflammatory Responses: Chemotactic Activity to Neutrophils and Association with Inflammatory Synovitis”, J. Biochem., vol. 122, pp. 453-458, 1997.
N. Maeda et al., “A Receptor-like Protein-Tyrosine Phosphatase PTPε/RPTPβ Binds a Heparin-Binding Growth Factor Midkine”, The Journal of Biological Chemistry, vol. 274, No. 18, pp. 12474-12479, Apr. 30, 1999.
M. Qi et al., “Haptotactic Migration Induced by Midkine”, The Journal of Biological Chemistry, vol. 276, No. 19, pp. 15868-15875, May 11, 2001.
M. Cotten et al., “2′-O-methyl, 2′-O-ethyl oligoribonucleotides and phosphorothioate oligodeoxyribonucleotides as inhibitors of the in vitro U7 snRNP-dependent mRNA processing event”, Nucleic Acids Research, vol. 19, No. 10, pp. 2629-2635, 1991.
B. S. Sproat et al., “New synthetic routes to synthons suitable for 2′-O-allyloligoribonucleotide assembly”, Nucleic Acids Research, vol. 19, No. 4, pp. 733-738, 1991.
M. Zuker, “Mfold webe server for nucleic acid folding and hybridization prediction”, Nucleic Acids Research, vol. 31, No. 13, pp. 3406-3415, 2003.
A. Murasugi et al., “Production of native recombinant human midkine in the yeast,Pichia pastoris”, Protein Expression and Purification, vol. 27, pp. 244-252, 2003.
Supplementary European Search Report dated Oct. 13, 2009 in European Application No. EP 07 83 1829.
Chinese Office Action together with English translation issued Nov. 29, 2010 in corresponding Chinese Application No. 200780042428.0.
Shibata et al., “Nuclear Targeting by the Growth Factor Midkine,” Oct. 31, 2002, pp. 6788-6796.

Affiliated with

Also associated with

Rating

Aptamer against midkine and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Aptamer against midkine and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aptamer against midkine and use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4294284